Japanese Foundation For Cancer Research

This study is for people whose hormone-positive, HER2-negative breast cancer has returned in the breast or nearby lymph nodes after initial treatment. It tests if adding a drug called abemaciclib to standard hormone therapy is better at preventing the cancer from coming back or s…